Maria Baltazar is currently a Science Leader at the Safety & Environmental Assurance Centre of Unilever responsible for leading research teams developing new approach methodologies (NAMs) applied to next generation risk assessment for systemic toxicity. She joined Unilever in 2016 as a risk assessor in the skin allergy and immunology field and from 2018 to 2022 she led the Inhalation Research Group which developed new methods for assessing lung toxicity using 3D tissue models and computational tools. Maria received her Msc and PhD in Pharmaceutical Sciences from the Faculty of Pharmacy from the University of Porto in Portugal. While in Portugal, she was an invited Assistant Professor at the Advanced Institute of Health Sciences (Gandra, Portugal) where she lectured Food Toxicology Analysis in the BSc degree in Forensic and Criminal Sciences for two years. After graduating in 2014, she joined the fast consumer goods company Imperial Brands as a risk assessor. Maria is a frequent invited speaker at international conferences and webinars and recipient of two awards from the Society of Toxicology Risk Assessment Specialty Section. She has been appointed as industry representative in international consortia (e.g., Texas A&M Tissue Chip Validation Consortium) and in trade associations, both Cosmetics Europe and the International Consortium on Cosmetic Safety where she is currently the chair of the Safety Decision Delivery Team. Maria’s research passion is to advance the application of non-animal methods for safety assessment and ultimate regulatory acceptance.
Prof. Paul Carmichael has worked in the Safety & Environmental Assurance Centre (SEAC) of Unilever in the UK since 2004, where he is responsible for the development and implementation of novel non-animal-based approaches for assuring human and environmental health; that is to say, how can consumer and environmental safety be assured without using and harming animals? He has over thirty years’ experience in toxicology and cancer research, largely in the academic arena, and prior to Unilever, he was a Senior Lecturer at Imperial College London in the Faculty of Medicine, where he taught pharmacology and toxicology and conducted research into advances in toxicology. A graduate of Surrey University with a B.Sc. in Biochemistry/Toxicology and a Ph.D. from King’s College London, he was a postdoctoral scientist at the Institute of Cancer Research (Royal Marsden Hospital) for seven years, exploring mechanisms of chemical genotoxicity and carcinogenicity. He currently has close academic links with Peking University in China (the School of Public Health) and is an Adjunct Assistant Professor of Pathology and Laboratory Medicine at Brown University in the USA. He has been an Endowed Professor at Wageningen University, Division of Toxicology in the Netherlands, since March 2020. He has published over one hundred research papers in peer-reviewed scientific journals and has served or serves on many external committees in the UK, US, EU and China. His passion is the advancement of new safety assessment approaches using the inspiration of ‘Toxicity Testing in the 21st Century’ – this can be termed ‘next generation risk assessments’ or NGRA.
Qasim Chaudhry is currently a visiting Professor at University of Chester (UK). He has academic background in chemistry and biochemical toxicology, with longstanding expertise in health and environmental safety of food and other consumer products. His scientific career at the UK’s Food and Environment Research Agency (Fera) has encompassed assessing the health and environmental safety of chemicals and nanomaterials; in silico (computational) toxicology, natural products, development of immunodiagnostics, bioremediation, and modes of toxic action of chemicals. As an independent scientific Expert, Prof. Chaudhry provides his advice to the European Commission's Scientific Committee on Consumer Safety (SCCS); the European Food Safety Authority (EFSA); the UK's Food Standards Agency; and the UK’s Office for Product Safety and Standards.
Emanuela Corsini is a tenured full professor in toxicology at the School of Pharmacy at the Università degli Studi di Milano, Milan, Italy. As such, she organizes and teaches courses in the field of Toxicology at the School of Pharmacy and the School of Environmental Sciences, University of Milan. She has been active in training undergraduate and graduate students at her own university and has also developed and presented lectures for other academic institutions and professional societies. Her research focuses on the refinement of alternative in vitro tests for immunotoxicity, promoting the regulatory acceptance of alternative methods, and on the understanding the mechanism of action of immunotoxic/immunomodulatory compounds at the molecular level. Dr. Corsini has served on multiple ECVAM and ICCVAM Panels and Working groups to establish scientific confidence in alternative methods in immunotoxicology testing, performance standards for these novel assays and the development of integrated testing strategies for their use as part of comprehensive and predictive assessments. She has authored over 190 research publications in toxicology and related disciplines. She is active in numerous scientific and professional organizations and serves on several editorial boards of toxicology journals.
Wim H. De Jong, graduated as veterinarian at Utrecht University, the Netherlands in 1978 and is registered specialist in Experimental Pathobiology, and Toxicological Pathology. He worked as senior scientist at the National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands from which he retired in 2019. He obtained his PhD in May 1985 with the PhD thesis ”Immunotherapy of cancer with Bacillus Calmette-Guérin”. His research career started with experimental oncology studying immunostimulation as immunotherapy for cancer, and using liposomes to diminish chemotherapeutic toxicity for doxorubicin and cis-platin while keeping antitumor activity. He switched research to in vivo and in vitro assays for safety evaluation of biomaterials/medical devices and nanomaterials. His expertise includes safety evaluation and risk assessment of xenobiotics, biomaterials/medical devices and nanomaterials, and development of alternative testing methods for toxicological endpoints. He has publsihed over 180 papers in peer reviewed journals and several book chapters. He participated in several European projects on nanotoxicology and nanomaterial risk assessment. Dr De Jong has been a member of various national and international advisory working groups and committees e.g. ISO/TC 194, CEN/TC 206, EFSA, SCENIHR, SCHEER, and SCCS. He was chairman of ISO/TC 194, WG 8 on irritation and sensitization, and participated in many other working groups of ISO/TC 194 Biological and Clinical Evaluation of Medical Devices. He was member of ISO/TC 229 Nanotechnologies in Working Group 3 on Health, Safety and Environmental Aspects of Nanotechnologies. Currently he is a member of the Scientific Committee for Health, Environmental and Emerging Risks (SCHEER) of the European Commission, and member of the Scientific Committee on Consumer Safety (SCCS) Working Group on Nanomaterials in Cosmetic Products, that evaluates the safety and use of nanomaterial cosmetic ingredients. He is member of the editorial board and reviewer for several scientific journals including journals on particle toxicology such as Particle and Fiber Toxicology (PFT), and Nanotoxicology.
Biologist/Zoologist; Thesis in Genetic Toxicology (Technical University of Darmstadt 1987) Doctor in Biology/Zoology; Thesis in Immunotoxicology (Technical University of Darmstadt 1991) European Registered Toxicologist (since 2002)
Food Chemistry at the University of Kaiserslautern ; Thesis: Research on DNA- polymerase stops caused by selected N-nitrosoureas. Dr.rer.nat. at the University of Kaiserslautern, 1995 in the subject area: food chemistry and ecotoxicology with the thesis: N-nitroso-diethanolamine- analytic, study on inhibition and research on metabolic activation. European Registered Toxicologist (since 2005)
Carsten Goebel is currently leading the global product safety and regulatory affairs team at the Wella Company. This includes human safety leadership for the innovation program requiring toxicological research in the areas of skin sensitization and metabolism. He is a member of the German Society of Toxicology (DGPT)/EUROTOX and Immunology (DGfI) and a certified expert in both areas. He received his Ph.D. in Biology from the University of Düsseldorf, Germany, where his research focused on adverse immune effects of anti-rheumatic drugs including aromatic amines and the corresponding role of metabolic polymorphism. During his post-doc assignment, he was responsible for projects assessing the effect of xenobiotics on the immune system.
Currently, Carsten Goebel’s research is focused on better understanding the different exposure conditions of skin sensitization hazard and potency testing conditions (LLNA, HRIPT, diagnostic patch testing) compared to product use conditions with the goal to further refine current non-animal approaches for skin sensitization risk assessment. He has many peer-reviewed publications to his name and has published in journals including Regulatory Toxicology and Pharmacology, the British Journal of Dermatology and the Journal of Investigative Dermatology. Some of his most recent research established a new approach to quantitative risk assessment for skin sensitization of hair dye ingredients. This concept has been successfully applied to support the development of less sensitizing alternative hair dye molecules, such as 2-methoxymethyl-p-pehnylenediame, to improve the protection of hairdressers and hair color users from allergic contact dermatitis.
Prof. em. An Goossens became associated professor in 1990 and professor in 1996 at the Faculty of Medicine (KU Leuven), and was also, until 2011, guest professor at the Faculty of Pharmacy at the University of Antwerp. She was teaching dermato-cosmetics to pharmacists and medical students, specialization courses in contact dermatitis to dermatology residents and occupational dermatoses to occupational physicians. In October 2016, she retired as an “Emeritus professor with duties”, still giving courses to students in the Faculties of Medicine and Pharmaceutical Sciences (KU Leuven) until 2020. In 1982, she got a permanent position as a scientific co-worker in the Department of Dermatology (KU Leuven), where she became the head of the Contact allergy unit and has trained many national and international dermatology residents in this field. She also worked as an expert for the Federal Agency of Occupational Risks (FEDRIS) for patients with occupational dermatoses. She has been promotor of five doctoral theses and author or co-author of more than 400 articles in international peer reviewed scientific journals as well as of several book chapters. She was often invited to national and international congresses in the field of allergy and contact dermatitis. She is member and/or honorary member of the national and many international dermatological societies and member of the editorial board of scientific journals. She received several international awards, among which the International League of Dermatologic Societies (ILDS) Certificate of appreciation (2016).
Martine Grosber is head of the dermatology and allergology outpatient units of the University Hospital Brussels (UZ Brussel) since 2013. She studied medicine in Innsbruck (AT) and specialized in Dermatology in major university hospitals in Freiburg (D), Paris (F) and Munich (D). Her special interests are inflammatory skin diseases and allergies. She is member of the EAACI Drug Allergy Interest Group and the Belgian Contact and Environmental Dermatitis Group (BCEDG). She is a clinical tutor for dermatology at the Vrije Universiteit Brussels and full time supervisor for dermatology residents in the academic teaching hospital UZ Brussels. She organizes symposia on inflammatory skin diseases and allergies for general practitioners and dermatologists on a regular basis.
Since 1 September 2021, Nynke Kramer is associate professor in toxicology at the Toxicology Division of the Agrotechnology and Food Sciences group of Wageningen University. She teaches toxicology, toxicokinetics and (eco)toxicological risk assessment at undergraduate, graduate, and postgraduate level. Before starting at Wageningen University, she was assistant professor in toxicology at the Institute for Risk Assessment Sciences (IRAS) of Utrecht University, where she also obtained her PhD in 2010. Her research focusses on enhancing the uptake of in vitro models in chemical safety assessment by developing models extrapolating toxic concentrations in in vitro cell assays to toxic doses relevant to humans and animals. Her research has led to over forty peer-reviewed publications identifying physiological and chemical parameters underlying the accumulation of toxicants in cells in the body and in in in vitro toxicity assays. Illustratively, Nynke’s research has been awarded the SETAC Procter and Gamble Fellowship for Doctoral Research in Environmental Sciences. She used the prize money to do part of her research at the Swiss Federal Institute for Aquatic Science and Technology, Eawag, Dübendorf, Switzerland. Before starting her PhD, Nynke obtained her BSc degree in Life Sciences at University College Utrecht and her MSc degree in Environmental Change and Management at the University of Oxford. She currently is board member of INVITROM, the Dutch/Belgian Society on In Vitro Methods, and the in2TOX specialty section of EUROTOX, the Federation of European Toxicologist, as well as associate editor for Chemosphere.
Dr Ouédraogo is passionate about research on alternative methods to animal testing. As a native of Burkina-Faso in west Africa, getting access to higher education is a great privilege. She strives to sharing this privilege with as many persons (who share the same passion) as possible; and learn from others as well. The journey started as a student in pharmacy where she started wet lab experiments in a laboratory of photobiology. Since then, she contributed to different initiatives (including European Framework projects) and successfully established and led number of collaborations for l’Oréal. As a scientific officer in the industry, she built a network with experts from different companies, sectors, SMEs and academic laboratories. She joined l’Oréal in 2003 to develop in vitro genotoxicity and cell transformation assays. In 2006, she took the lead of the genotoxicity and cancer group and transitioned in 2010 to managing teams of scientists working on different endpoints like skin sensitization, systemic toxicity, phototoxicity, genotoxicity. Since 2013, she leads research initiatives mainly with external partners on repeated dose systemic toxicity and genotoxicity. She is the representative of the company in different working groups at Cosmetics Europe, EU-ToxRisk, Riskhunt3R, OECD, HESI.
Dr Gerald Renner was born in Graz (Austria) in 1967. His basic scientific training is in engineering chemistry at the Technische Universität Graz, where he graduated in 1993. After that he specialised in biochemical engineering and worked for his PhD at the Technische Universität Graz, and the Ecole Polytechnique de Montréal. He finished his doctoral studies on the bacterial production of biodegradable plastics in 1996. After additional courses in animal cell culture techniques and immunology at the Université Libre de Bruxelles, he joined the Colipa (now Cosmetics Europe) Scientific department at the end of 1996. Since 2001 he is Cosmetic Europe’s Director of Technical Regulatory Affairs which includes since 2010 also the association s activities on international regulatory convergence.
After many years of leading the department of In Vitro Toxicology and Dermato-Cosmetology at the VUB in a successful way, Emeritus professor in Toxicology Vera Rogiers is actually still teaching dermato-cosmetics at the VUB and the University of Ghent. She also gives a limited number of lessons to the University of Namur. She yearly organizes international courses on Cosmetics and Risk Assessment. She is the Director of the Innovation Centre-3Rs (IC-3Rs) at the VUB and of the scientific Chair Mireille Aerens, both with focus on replacing experimental animals by novel technologies. At the EU level, she is co-chair of the Scientific Committee on Consumer Safety (SCCS) and member of the Mirror group of the European Partnership on Alternative Approaches to Animal Testing (EPAA). Her main research activity was many years situated in the development of in vitro models as an alternative to the use of experimental animals. Actual focus is on the differentiation of human skin-derived stem cells to functional hepatic cells and their application for drug discovery and the detection of drug-induced liver injury. She has been promoter of 33 doctoral theses, is author or co-author of >380 publications in international peer reviewed scientific journals and is editor of several scientific books. She is an often-invited speaker (>350) and participated in the organization of more than 60 international congresses. She has coordinated 2 EU research projects and was partner in several FP6, FP7 EU and Horizon 2020 research projects concerned with in vitro methodology development. Of the obtained scientific results, several patents have been filed. Throughout her carrier she received several international scientific awards for her pioneering role in in vitro Experimental Toxicology.
Since 2007, he is heading the global Toxicology department in Front End Innovation of Beiersdorf in Hamburg (Germany), focusing on development of alternative methods (NAMs) in the fields of Skin bioavailability and Sensitization, Mutagenicity, Irritation, ADME and digital toxicology. He is chairing Cosmetic Europe’s Task Force Skin Bioavailability/ADME in the Long Range Science Strategy Program since 2013. Dr. Schepky is a full member of the SOT, British Toxicology Society, the European Society of Toxicology in vitro as well as of the German Society of Pharmacology and Toxicology. He is author or co-author of multiple publications in international peer reviewed scientific journals and books with focus on alternatives to animal testing method development, performing case studies and proposing frameworks, including in vitro and digital toxicology approaches.
From 1989 till his early retirement in 2018 he was responsible as a senior toxicologist for the safety of global consumer goods (mainly cosmetic products) at Henkel AG & Co KGaA.
He worked in several committees and expert groups like the OECD, ECETOC, and Cosmetics Europe. During this time, he published about 100 articles and abstracts in international scientific journals and gave about 50 presentations at international congresses like the World Congresses on Alternative Methods, INVITOX, PPP, EUROTOX predominately on alternative methods.
Since more than two decades he is giving lectures on toxicological topics at the German Universities of Düsseldorf, Witten, and Leipzig, in Frankfurt, and Brussels/Belgium and supervised toxicological master theses. Currently, he is a reviewer for several international scientific journals.
Since 2019 he works as an expert in the German governmental development organization SES (Senior Expert Services).
Freddy obtained his Ph.D. degree in Science at the Free University of Brussels (Belgium) in 1995. After his post-doc, he joined Janssen (Belgium) as a Study Director for In Vitro, Genetic and Predictive toxicology. From 2003 to 2009, Freddy was the chairman of the Belgian Environmental Mutagen Society. During his career, he was responsible for the identification and validation of new in vitro test systems to assess the safety profile of compounds in early drug development. Today, he’s heading the Cell Health Assessment group of Janssen, who is responsible for high throughput liability screening and the development of a next generation in vitro predictive toxicology strategy.
Dr. Matthias Vey is a chemist by training from the Technical University of Darmstadt, Germany. After his studies and a short period of training as a perfumer he started in fragrance research and development for Marbert Cosmetics in Düsseldorf, Germany. He then became global regulatory affairs manager for Coty/Lancaster in Mainz, Germany.
In 2000 Dr. Vey joined IFRA. As Vice President Scientific Affairs, he is responsible for the fragrance industry's worldwide safe use program, known as the IFRA Standards. He also manages all of IFRA's science related committees and is involved in IFRA's advocacy activities. He is responsible for the management of the International Dialogue on the Evaluation of Allergens (IDEA), a multi-stakeholder initiative. He regularly presents at international meetings and conferences.
The Safety Training Course will be held from Monday 6 February to Saturday 11 February 2023 at the Vrije Universiteit Brussel, Medical Campus Jette, Laarbeeklaan 103, 1090 Brussels, Belgium.
We’re handling online registration and online payment by credit card. Every registrant will automatically receive a PAID invoice.
The official language of the course is English. No simultaneous translation will be provided.
The registrations fees for the Safety Assessment of Cosmetics in the EU will be:
Early Bird Registration fee (till 30 November 2022):
4.000 euro per participant
Regular Registration fee (from 1 December 2022):
4.950 euro per participant
Students: 1.100 euro per participant. Students are kindly requested to send their proof of being a student in sciences (chemistry, toxicology, pharmacy, medical doctor, biotechnology, etc...) to Fabienne Van Bamis to receive their unique discount code.
The course fee, payable by credit card covers all lessons, the course material and the participation to the exam. Also included are all the coffee breaks, lunches, the shuttle between the hotel & the campus and the social event.
nhow Brussels Bloom ****, Rue Royale 250, 1210 Brussels, Belgium
T: +32 (0)2 220 66 11 • F: +32 (0)2 217 84 44
The nhow Brussels Bloom, formerly known as NH Brussels Bloom, is a place where globetrotters, business travelers and locals get together to eat, sleep, drink and create. Originally built in the 1970s, the hotel used to be Brussels’ most exclusive property and regularly welcomed stars like Michael Jackson and President Ronald Reagan. Throughout the years, the hotel has evolved from the most exclusive hotel in Brussels to an art hotel that celebrates creativity.
Today, the hotel is decorated in a contemporary and stylish fashion. Plus, it’s packed with high-end furnishings, services and facilities. During your stay, you can workout with a view of the Brussels skyline on the eighth floor, grab breakfast at the Instagram-friendly Waffle Bar or explore the art installations that bring this wonderful building to life. The nhow Brussels Bloom is located in the lively Botanique area of Brussels. It’s surrounded by parks, concert venues and art galleries. In fact, it’s in the perfect spot for any art and culture enthusiast. Due to the hotel’s location, you’ll find it easy to explore the Grand Place, gorge on waffles and visit the Rue Neuve shopping district.
An innovative art hotel that celebrates creativity • In the Botanique area of the city, surrounded by museums, galleries and green spaces • 15 minutes away from Brussels airport and 10 minutes away from Brussels North station on foot
The hotel’s 305 guest rooms and suites have all been designed and decorated to replicate the appearance of an art gallery. While the blank and spacious rooms will spark your inspiration, the bathrooms replicate a photography darkroom. Most rooms also come with a city view and each contains modern luxuries like a coffee machine, an extra-wide flat screen television and an oversized infinity work desk.
A free shuttle bus service will operate on a daily basis between nhow Brussels Bloom and the university.
Rates
During the course you can stay at nhow Brussels Bloom at very special, well-negotiated rate. The rates are 120,00 euro/night from Saturday till Monday and 170,00 euro/night from Tuesday till Friday (breakfast, internet, fitness… included).
With OVER 20 YEARS OF EXPERIENCE in organizing the 'Safety Assessment of Cosmetics in the EU – Training Course', we can provide you with a sound and independent scientific counselling with regard to safety of cosmetic and their ingredients for the EU market*:
• development and/or improvement of your Product Information File (PIF)
Part A: cosmetic product safety information
Part B: cosmetic product safety assessment
• support and guidance in general cosmetic safety assessment
• advise on regulatory requirements (product adherence with EU legislation)
• ensuring that information about your cosmetic products is accurate and well presented
• INCI Ingredient labelling
• Cosmetovigilance – follow up assessment
* According to the Cosmetic Regulation EC N° 1223/2009 cosmetics circulating in Europe must demonstrate the evidence of their conformity with the stipulated requirements in the form of a Product Information File (PIF). A PIF is the mandatory compilation of technical documentation with regard to the description, the manufacturing methods, claims substantiation and a Cosmetic Product Safety Report.
CANCELLATION POLICY
Registered participants who cannot attend the course may apply for a refund of the registration fee. A substitute delegate is, of course, welcome. Notification is made via e-mail. The participant is entitled to a refund, minus a service fee, according to the following guidelines:
Regrettably, no refunds will be made if notification is made less than 5 business days prior to the course.
